151 related articles for article (PubMed ID: 24451214)
1. Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.
Thareja S; Zager JS; Sadhwani D; Thareja S; Chen R; Marzban S; Jukic DM; Glass LF; Messina J
Am J Dermatopathol; 2014 Jan; 36(1):64-7. PubMed ID: 24451214
[TBL] [Abstract][Full Text] [Related]
2. Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain.
Ottmann K; Tronnier M; Mitteldorf C
J Am Acad Dermatol; 2015 Oct; 73(4):637-44. PubMed ID: 26278815
[TBL] [Abstract][Full Text] [Related]
3. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
4. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.
Casper DJ; Ross KI; Messina JL; Sondak VK; Bodden CN; McCardle TW; Glass LF
Am J Dermatopathol; 2010 Oct; 32(7):650-4. PubMed ID: 20559123
[TBL] [Abstract][Full Text] [Related]
5. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.
Schimming TT; Grabellus F; Roner M; Pechlivanis S; Sucker A; Bielefeld N; Moll I; Schadendorf D; Hillen U
Am J Dermatopathol; 2012 May; 34(3):266-9. PubMed ID: 22197861
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
7. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
8. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
9. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.
Ikenberg K; Pfaltz M; Rakozy C; Kempf W
J Cutan Pathol; 2012 Mar; 39(3):324-30. PubMed ID: 22335591
[TBL] [Abstract][Full Text] [Related]
12. Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Schmidt H; Steiniche T
Diagn Pathol; 2016 Apr; 11():35. PubMed ID: 27062658
[TBL] [Abstract][Full Text] [Related]
13. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
16. [Application of sentinel lymph node biopsy in patients with melanoma].
Ren M; Kong YY; Cai X; Shen XX; Lyu JJ
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):360-365. PubMed ID: 29783803
[No Abstract] [Full Text] [Related]
17. Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one.
Sekula-Gibbs SA; Shearer MA
Dermatol Surg; 2011 Aug; 37(8):1080-8. PubMed ID: 21635622
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis.
Jin C; Huang Y; Nasim M; Yang Y; Lee L
Int J Surg Pathol; 2019 Oct; 27(7):706-712. PubMed ID: 31146625
[No Abstract] [Full Text] [Related]
19. Sentinel lymphadenectomy for staging patients with intermediate-level melanoma.
Smart KR; Cahoon BW; Dale PS
Am Surg; 2000 Mar; 66(3):280-3. PubMed ID: 10759200
[TBL] [Abstract][Full Text] [Related]
20. Tumor Budding Detection by Immunohistochemical Staining is Not Superior to Hematoxylin and Eosin Staining for Predicting Lymph Node Metastasis in pT1 Colorectal Cancer.
Okamura T; Shimada Y; Nogami H; Kameyama H; Kobayashi T; Kosugi S; Wakai T; Ajioka Y
Dis Colon Rectum; 2016 May; 59(5):396-402. PubMed ID: 27050601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]